Contemporary trends in management of uveal melanoma

Neil Chevli, MD, Raed J. Zuhour, MD, Joy A. Messer, MD, Waqar Haque, MD, Amy C. Scheffler, MD, Eric H. Bernicker, MD, Patricia Chevez-Barrios, MD, Andrew M. Farach, MD, E. Brian Butler, MD, Bin S. Teh, MD

1 Department of Radiation Oncology, University of Texas Medical Branch at Galveston, Galveston, TX, USA, 2 Department of Radiation Oncology, Houston Methodist Hospital, Houston, TX, USA, 3 Retina Consultants of Houston, Houston, TX, USA, 4 Department of Medical Oncology, Houston Methodist Hospital, Houston, TX, USA, 5 Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX, USA

Abstract

Purpose: In the management of uveal melanoma, eye plaque brachytherapy (EPBT) has replaced enucleation as the standard of care for small size tumors that require treatment, and for medium size tumors. In the modern era, EPBT is being utilized more frequently for certain large tumors as well. While there is prospective randomized evidence to support utilization of EPBT for tumors of appropriate dimensions, it is unclear what the actual practice patterns are across the United States. The purpose of this publication was to look at contemporary trends in the management of uveal melanoma across the United States to determine whether practices are appropriately adopting EPBT, and to investigate demographic and socio-economic factors that might be associated with deviations from this standard of care.

Material and methods: The National Cancer Database was queried (2004-2015) for patients with uveal melanoma. Data regarding tumor characteristics and treatment were collected. Two-sided Pearson χ² test was used to compare categorical frequencies between patients who received globe preserving treatments vs. those who received enucleation. Multivariable logistic regression modeling was used to determine characteristics predictive for receiving enucleation.

Results: The enucleation rate for small/medium tumors (≤ 10 mm apical height and ≤ 16 mm basal diameter) decreased from 20% in 2004 to 10% in 2015. The EPBT rate for large tumors increased from 30% in 2004 to 45% in 2015. Numerous demographic and socio-economic factors were found to be associated with higher rates of enucleation.

Conclusions: The overall trend across the nation is a decreased enucleation rate for small/medium tumors, and an increased EPBT rate for large tumors. A fraction of patients who should be candidates for EPBT are instead receiving enucleation, and in this study, we have shown that certain adverse demographic factors are associated with this.

Key words: eye plaque brachytherapy, uveal melanoma, enucleation.

Purpose

Uveal melanoma is a rare malignancy, with an incidence of approximately 1,500 cases per year in the United States [1]. Standard of care for uveal melanoma depends on tumor size [2] (Table 1). Treatment modalities that have been utilized for uveal melanoma include observation for certain small tumors, eye plaque brachytherapy (EPBT), proton therapy, stereotactic radio-surgery (SRS), globe preserving surgeries, such as local tumor destruction, and non-globe preserving surgeries (i.e., enucleation) [3]. Based on a prospective randomized controlled trial, EPBT became the standard of care for small size tumors that require treatment and for medium size tumors, and because it is globe-preserving, it shows comparable survival rates compared to enucleation, has a low rate of local failure, and can be successfully salvaged with enucleation [4].

Historically, enucleation was the preferred treatment for large tumors because the available eye-plaques were not large enough to adequately cover these lesions. However, due to the introduction of custom eye-plaques, utilization of ultrasound for intra-operative optimization of plaque positioning and improvement in treatment planning software are now feasible to treat certain large tumors with EPBT [5, 6]. The most recent American Brachytherapy Society (ABS) guidelines stipulate that EPBT may be used for large uveal melanoma, if basal diameters do not exceed the limits of brachytherapy, and there is ≤ 5 mm extra-ocular extension [7]. These guidelines are supported by a handful of contemporary stud-
ies, which have reported acceptable outcomes with EPBT in large uveal melanoma [8-12].

Although prospective randomized evidence supports EPBT as the procedure of choice for small/medium tumors, and multiple studies demonstrate feasibility of EPBT in certain large tumors, it is unclear whether practice patterns reflect this. Because it is a rare malignancy, only facilities with adequate patient volume have the incentive to acquire the expertise and resources to implement a successful EPBT program. Analysis of SEER database shows that in the post-COMS era, there has been an overall increase in the percentage of patients receiving radiotherapy and a decrease in the percentage of patients receiving surgery [13, 14]. However, the SEER database studies do not specify the radiation treatment modality employed, and they do not differentiate between enucleation and globe-preserving surgeries, such as local tumor destruction. The purpose of this publication was to look at contemporary trends in the management of uveal melanoma to determine whether practices are appropriately adopting EPBT, and to investigate what demographic and socio-economic factors might be associated with deviations from this standard of care.

Material and methods

Data source and study population

The National Cancer Database (NCDB) is a joint project of the Commission on Cancer (CoC) of the American College of Surgeons (ACoS) and the American Cancer Society. The NCDB collects data from more than 1,500 hospitals with ACoS-accredited cancer programs, accounting for 70% of all newly diagnosed cancers cases in the United States [15-17]. It includes data on tumor characteristics, patient demographics, and survival. Thresholds for income and education were based on NCDB categorization. Thresholds for age and distance traveled were selected by rounding median value. NCDB is not a population-based registry, and under-represents rural areas and minority populations [18]. All pertinent cases are reported regularly from CoC-accredited centers and compiled into a unified dataset, which is then validated. Data used in the study were derived from a de-identified participant user file (PUF) [19]. It was therefore exempted from institutional review board oversight.

Patients’ selection

The NCDB database was queried (2004-2015) for all patients aged 18 or older, with a histologically confirmed diagnosis of uveal melanoma. Patients with nodal disease or distant metastasis at diagnosis were excluded from the analysis. Patients were categorized based on their first treatment modality. Therefore, patients who received a globe preserving treatment followed by enucleation were categorized in the former cohort. Due to missing stage data in some patients and changes in staging from American Joint Committee on Cancer (AJCC) 6\textsuperscript{th} edition to AJCC 7\textsuperscript{th} edition, tumor dimension information and available stage data were utilized to categorize tumors as either small/medium ($\leq 10$ mm apical height and $\leq 16$ mm basal diameter) or large ($> 10$ mm apical height or $> 16$ mm basal diameter). Due to stage migration and missing data, it was not feasible to accurately separate small lesions from medium lesions.

Data analysis

Two-sided Pearson $\chi^2$ test was used to compare categorical frequencies between patients who received globe preserving treatments vs. those who received enucleation. Line graphs were produced to visualize trends in epidemiology and management of uveal melanoma. Multivariable logistic regression modeling was used to determine characteristics predictive for receiving enucleation. Statistical analysis was conducted using RStudio version 1.2.1335 (R foundation for statistical computing, 2019).

Results

Of the 15,925 patients with histologically confirmed uveal melanoma, a total of 15,662 patients (98.3%) did not have metastatic disease at diagnosis, and thus met the inclusion criteria. Overall, the mean age was 63 years. The mean age was 64 years in the globe preserving treatment cohort, and 62 years in the enucleation cohort. Overall, the number of patients diagnosed with uveal melanoma in participating CoC facilities throughout 2004-2015 averaged 1,327 (range, 1,082-1,459) cases per year (Fig. 1). A total of 9,930 tumors (63%) were classified as small/medium size, 3,336 tumors (21%) were classified as large size, and no size could be determined for the remaining tumors (15%).

Table 1. Size definitions based on COMS classification

| COMS categories | Basal diameter | Apical height |
|-----------------|----------------|--------------|
| Small           | $\leq 16$ mm   | $< 2.5$ mm   |
| Medium          | $\leq 16$ mm   | 2.5-10 mm    |
| Large           | $> 16$ mm (or $> 8$ mm if $< 2$ mm from optic disc) | $> 10$ mm |

![Fig. 1. Number of patients diagnosed in participating Commission on Cancer (CoC) facilities by year](image-url)
### Table 2. Comparison of demographic data of all patients

| Variable                                      | Overall | Globe preserving treatment | Enucleation | p-value |
|-----------------------------------------------|---------|-----------------------------|-------------|---------|
| n                                             | 15,662  | 12,495 (80)                 | 3,167 (20)  |         |
| Age > 60 years (%)                            | 9,094 (58) | 7,311 (59) | 1,783 (56) | 0.026   |
| Gender (% male)                               | 8,115 (52) | 6,335 (51) | 1,780 (56) | < 0.001 |
| Race (%)                                      |         |                             |             | 0.022   |
| Non-white                                     | 319 (2)  | 239 (2)                     | 80 (3)      |         |
| White                                         | 14,915 (95) | 11,928 (96) | 2,987 (94) |         |
| Unknown                                       | 428 (3)  | 328 (3)                     | 100 (3)     |         |
| Median income zip code (%)                    |         |                             |             | < 0.001 |
| < $46,000                                     | 6,266 (40) | 4,798 (38) | 1,468 (46) |         |
| ≥ $46,000                                     | 9,262 (59) | 7,590 (61) | 1,672 (53) |         |
| Unknown                                       | 134 (1)  | 107 (1)                     | 27 (1)      |         |
| Residence setting (%)                         |         |                             |             | < 0.001 |
| Urban                                         | 10,154 (65) | 8,202 (66) | 1,952 (62) |         |
| Rural                                         | 5,104 (33) | 3,970 (32) | 1,134 (36) |         |
| Unknown                                       | 404 (3)  | 323 (3)                     | 81 (3)      |         |
| Distance traveled (%)                         |         |                             |             | < 0.001 |
| < 60 miles                                     | 7,905 (51) | 6,092 (49) | 1,813 (57) |         |
| ≥ 60 miles                                     | 7,635 (49) | 6,303 (51) | 1,332 (42) |         |
| Unknown                                       | 122 (1)  | 100 (1)                     | 22 (1)      |         |
| Education zip code (%)                        |         |                             |             | < 0.001 |
| < 13% without high school education           | 9,525 (61) | 7,788 (62) | 1,737 (55) |         |
| ≥ 13% without high school education           | 6,008 (38) | 4,603 (37) | 1,405 (44) |         |
| Unknown                                       | 129 (1)  | 104 (1)                     | 25 (1)      |         |
| Insurance (%)                                 |         |                             |             | < 0.001 |
| Uninsured                                     | 515 (3)  | 305 (2)                     | 210 (7)     |         |
| Government                                    | 6,880 (44) | 5,449 (44) | 1,431 (45) |         |
| Private                                       | 7,685 (49) | 6,366 (51) | 1,319 (42) |         |
| Unknown                                       | 582 (4)  | 375 (3)                     | 207 (7)     |         |
| Facility type (%)                             |         |                             |             | 0.003   |
| Non-academic                                  | 3,787 (24) | 2,961 (24) | 826 (26)   |         |
| Academic                                      | 10,841 (69) | 8,728 (70) | 2,113 (67) |         |
| Unknown                                       | 1,034 (7) | 806 (7)                    | 228 (7)     |         |
| Treated in experienced facility (defined by median) (%) | 7,651 (49) | 6,520 (85) | 1,131 (15) | < 0.001 |
| Charlson-Deyo score (%)                       |         |                             |             | 0.019   |
| 0                                             | 13,056 (83) | 10,358 (83) | 2,698 (85) |         |
| 1                                             | 2,174 (14) | 1,787 (14) | 387 (12)   |         |
| 2                                             | 331 (2)  | 269 (2)                     | 62 (2)      |         |
| 3                                             | 101 (1)  | 81 (1)                      | 20 (1)      |         |
| COMS size (%)                                 |         |                             |             | < 0.001 |
| Small/medium                                  | 9,930 (63) | 8,753 (70) | 1,177 (37) |         |
| Large                                         | 3,336 (21) | 1,882 (15) | 1,454 (46) |         |
| Unknown                                       | 2,396 (15) | 1,860 (15) | 536 (17)   |         |
| Ciliary body involvement (%)                  | 1,841 (12) | 1,305 (10) | 536 (17)   | < 0.001 |
| Extra-ocular extension (%)                    | 750 (5)  | 337 (3)                     | 413 (13)    | < 0.001 |
| Enucleation (%)                               | 3,167 (20) | 2,987 (94) | 1,277 (41) |         |
Table 2. Cont.

| Variable                        | Overall | Globe preserving treatment | Enucleation | p-value |
|---------------------------------|---------|----------------------------|-------------|---------|
| Globe preserving modality (%)   | 12,495  |                           |             |         |
| EPBT alone                      | 9,263   |                           |             |         |
| EPBT + LTD                      | 696     |                           |             |         |
| PT                              | 1,194   |                           |             |         |
| SRS                             | 96      |                           |             |         |
| LTD alone                       | 486     |                           |             |         |
| No treatment                    | 443     |                           |             |         |
| Other/unknown                   | 317     |                           |             |         |

Table 2 displays clinico-pathologic characteristics of the study population. A total of 12,495 (80%) patients received globe preserving treatment, while 3,167 (20%) patients received enucleation. Compared to patients who received globe preserving treatments, patients who received enucleation were more likely to be males, ≤ 60 years old, and non-white race. Socio-economically, these patients were more likely to live in a zip code with a lower median income, live in a zip code with a lower education level, live in a rural region, travel < 60 miles to the treating facility, and not have insurance. Additionally, these patients were more likely to be treated in a non-academic site and be treated in an inexperienced facility (defined as a facility that treated less than median number of patients relative to all facilities overall). Clinically, these patients were more likely to have a lower Charlson-Deyo combined comorbidity (CDCC) score, have large tumors, have ciliary body involvement, and have extra-ocular extension. The overall trend from 2004 to 2015 was 5% less patients receiving enucleation, and 5% more patients...
receiving EPBT (Fig. 2A). The percent of patients receiving proton therapy or local tumor destruction remained largely unchanged (Fig. 2A). In the small/medium tumor cohort, the enucleation rate decreased from 20% in 2004 to 10% in 2015 (Fig. 2B). In the large tumor cohort, the EPBT rate increased from 30% in 2004 to 45% in 2015, while the enucleation rate remained largely unchanged (Fig. 2C).

On multivariable logistic regression analysis, demographic factors independently predictive for receiving enucleation included male gender, age ≤ 60 years old, and non-white race (Fig. 3). Socio-economic factors independently predictive for receiving enucleation included residence in a zip code with lower median income, residence in a zip code with lower education level, rural residence, traveled < 60 miles to the treating facility, and not having insurance (Fig. 3). Facility-related factors independently predictive for receiving enucleation included treatment at a non-academic site and treatment in an inexperienced facility (Fig. 3). Clinical factors independently predictive for receiving enucleation included large tumor, ciliary body involvement, and extra-ocular extension (Fig. 3).

Discussion

In the largest study to date evaluating contemporary treatment trends for uveal melanoma, our results show that the upfront enucleation rate for small/medium tumors decreased from 20% in 2004 to 10% in 2015. This decrease in enucleation rate suggests expanding implementation of EPBT as the accepted standard of care for tumors of these dimensions. For large tumors, our results showed an increased EPBT rate from 30% in 2004 to 45% in 2015, suggesting that with the development of modern eye-plaques providers, the increased comfort in offering this therapy for lesions that historically could not be treated with EPBT.

Overall, the number of patients diagnosed with uveal melanoma in participating CoC facilities has increased to a similar rate of US population throughout 2004-2015. In general, brachytherapy is becoming more prominent relative to surgery because there is increasing evidence for its role, growing emphasis on providing adequate brachytherapy training to radiation oncology trainees, and increasing communication between surgeons and radiation oncologists [20]. Furthermore, recent evidence has demonstrated poor overall survival (OS) with proton therapy compared to EPBT, and this may explain why proton therapy utilization decreased from 20% to < 10% for large size tumors in the present study [21].

Our analysis suggests there may be numerous reasons why a small but meaningful number of small/medium tumors are still being treated with enucleation. EPBT is a specialized procedure that requires a skilled ocular oncologist and an experienced radiation oncologist. Because there are only approximately 1,500 cases a year, there are only a limited number of centers with sufficient expertise in this procedure. Centers with this level of expertise are typically academic sites. As expected, our findings suggest that patients who received enucleation were more likely to be treated in an inexperienced facil-

| Variable                      | Risk ratio (95% CI) | p-value |
|-------------------------------|--------------------|---------|
| Age > 60                      | 0.89 (0.81-0.99)   | 0.026   |
| Male gender                   | 1.23 (1.12-1.36)   | < 0.001 |
| White race                    | 0.75 (0.61-0.93)   | 0.009   |
| Income (of zip code)          | 0.73 (0.65-0.83)   | < 0.001 |
| Low education (of zip code)   | 1.15 (1.03-1.29)   | 0.017   |
| Rural region                  | 1.43 (1.27-1.61)   | < 0.001 |
| Traveled > 60 miles to facility| 0.63 (0.56-0.71)   | < 0.001 |
| Uninsured                     | 2.23 (1.77-2.80)   | < 0.001 |
| Academic facility             | 1.14 (1.02-1.27)   | 0.020   |
| Experienced facility          | 0.45 (0.40-0.50)   | < 0.001 |
| CDCC score                    | 0.88 (0.76-1.00)   | 0.052   |
| Large tumor                   | 5.97 (5.39-6.63)   | < 0.001 |
| Ciliary body involvement      | 2.30 (1.97-2.67)   | < 0.001 |
| Extra-ocular extension        | 4.21 (3.54-5.01)   | < 0.001 |

Fig. 3. Forest plot of multivariable logistic regression for factors independently associated with undergoing enucleation. Scale is logarithmic.
ity and non-academic site. We suspect that patients who live in a rural region, in an area with a lower median income, and in a region with a lower educational level were more likely to receive enucleation because they ended up being treated at an inexperienced facility and non-academic site. Likewise, we suspect that those who traveled < 60 miles to the treatment facility were more likely to receive enucleation because they were more likely to have not traveled to a more experienced facility. We speculate that patients of non-white race and without insurance were more likely to receive enucleation because of their lower socio-economic means, and therefore might not have been able to get treatment in a more experienced facility that could offer EPBT. Alternatively, patients of non-white race may be more likely to live in an urban region, which may be a confounding factor. It is unclear why patients ≤ 60 years old and male patients were more likely to receive enucleation. Overall, these socio-economic and regional disparities highlight the importance of initiatives to remove barriers for patients, and to encourage ophthalmologists to refer patients to experienced centers for the management of uveal melanoma.

We suspect that the increased utilization of EPBT for large tumors is due to the advancements in EPBT technology, such as custom plaque designs, intra-operative optimization of plaque positioning using ultrasound, and developments in EPBT treatment planning systems [5, 22, 23]. The COMS trial evaluating EPBT excluded tumors of > 16 mm in basal diameter because the eye-plaques available at that time were not big enough to cover tumors larger than this. A limitation of the current study was that data related to these technological advancements were not recorded in the NCDB, so we were unable to evaluate our suspected association between technological advancements and increased utilization of EPBT for large tumors.

Additional limitations of this study included stage migration from AJCC 6th edition to AJCC 7th edition and the missing data related to variables, including stage, tumor depth, tumor basal diameter, ciliary body involvement, and extra-ocular extension. This limitation prevented us from accurately delineating stage beyond a basic stratification of small/medium tumors and large tumors. Also, the retrospective nature of the study was recognized as a limitation and precluded establishing causal relationships. The NCDB is not a population-based registry and under-represents rural areas and minority populations, because these populations of patients are less likely to be treated in ACoS-accredited cancer programs. Furthermore, the NCDB does not include various additional clinical details, which would be beneficial to the analysis, such as gene expression profile of tumors, local control, and toxicity.

Conclusions

In conclusion, we demonstrated a trend of decreased enucleation for small/medium tumors and increased EPBT for large tumors. A fraction of patients who should be candidates for globe-preserving treatment are instead receiving enucleation, and certain adverse demographic factors are associated with this.

Disclosure

The authors report no conflict of interest.

References

1. Ramaiya KJ, Harbour JW. Current management of uveal melanoma. Expert Rev Ophthalmol 2007; 2: 959-946.
2. Swetter SM, Thompson JA, Albertini MR et al. NCCN Guidelines Uveal Melanoma Version 2.2021. https://www.nccn.org/professionals/physician_gls/pdf/uveal.pdf (accessed: December 1, 2021).
3. Factors predictive of growth and treatment of small choroidal melanoma: COMS Report No. 5. The Collaborative Ocular Melanoma Study Group. Arch Ophthalmol 1997; 115: 1537-1544.
4. The COMS Randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS Report No. 28. Arch Ophthalmol 2006; 124: 1684-1693.
5. Tann AW, Teh BS, Scarborough SB et al. Early outcomes of uveal melanoma treated with intraoperative ultrasound guided brachytherapy using custom built plaques. Pract Radiat Oncol 2017; 7: e275-e282.
6. Wong AJ, Teh BS, Nguyen BT et al. Late midterm outcomes of uveal melanoma treated with intraoperative ultrasound guided 1125 brachytherapy using custom built eye plaques. Int J Radiat Oncol Biol Phys 2020; 108: e747-e748.
7. Simpson ER, Gallie B, Laperriere N et al. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy 2014; 13: 1-14.
8. Chevli N, Schefler AC, Brogna ME et al. Staged eye-plaque brachytherapy: a novel approach for large uveal melanoma. Adv Radiat Oncol 2021; 6: 100712.
9. Messer JA, Zuhour RJ, Haque W et al. Eye plaque brachytherapy versus enucleation for ocular melanoma: an analysis from the National Cancer Database. J Contemp Brachytherapy 2020; 12: 303-310.
10. King BA, Awh C, Gao BT et al. Iodine-125 episcleral plaque brachytherapy for AJCC T4 posterior uveal melanoma: clinical outcomes in 158 patients. Ocul Oncol Pathol 2019; 5: 340-349.
11. Puusaari I, Heikonen J, Summanen P et al. Iodine brachytherapy as an alternative to enucleation for large uveal melanomas. Ophthalmologica 2003; 110: 2223-2234.
12. Fontanesi J, Meyer D. Treatment of large melanomas with split-plaque technique. Endocuriether Hypertherm Oncol 1995; 11: 9-13.
13. Singh AD, Turell ME, Topham AK. Uveal melanoma trends in incidence, treatment, and survival. Ophthalmology 2011; 118: 1881-1885.
14. Aronow ME, Topham AK, Singh AD. Uveal melanoma: 5-year update on incidence, treatment, and survival (SEER 1973-2015). Ocul Oncol Pathol 2018; 4: 145-151.
15. Stauber J, Chevli N, Haque W et al. Prognostic impact of radiation therapy in tubular carcinoma of the breast. Radiother Oncol 2021; 159: 202-208.
16. Haque W, Singh A, Verma V et al. Postmastectomy radiation therapy following pathologic complete nodal response to neoadjuvant chemotherapy: A prelude to NSABP B-51? Radiother Oncol 2021; 162: 52-59.
17. Al Feghali KA, Buszek SM, Elhalawani H et al. Real-world evaluation of the impact of radiotherapy and chemotherapy in elderly patients with glioblastoma based on age and performance status. Neurooncol Pract 2020; 8: 199-208.
18. McClelland S, Perez CA, Perez CA. The pervasive crisis of diminishing radiation therapy access for vulnerable popu-
lations in the United States-part 3: Hispanic-American patients. Adv Radiat Oncol 2018; 3: 93-99.
19. National Cancer Database Participant Use Data File (PUF) DataDictionary,2014.https://www.facs.org/-/media/files/quality-programs/cancer/ncdb/puf_data_dictionary_2015.ashx (accessed: December 1, 2021).
20. Tagliaferri L, Vavassori A, Lancellotta V et al. Can brachytherapy be properly considered in the clinical practice? Trilogy project: The vision of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) Interventional Radiotherapy study group. J Contemp Brachytherapy 2020; 12: 84-89.
21. Lin AJ, Rao YJ, Acharya S et al. Patterns of care and outcomes of proton and eye plaque brachytherapy for uveal melanoma: review of the National Cancer Database. Brachytherapy 2017; 16: 1225-1231.
22. Semenova E, Finger PT. Palladium-103 plaque radiation therapy for American Joint Committee on Cancer T3- and T4-Staged choroidal melanomas. JAMA Ophthalmol 2014; 132: 205-213.
23. Binder C, Mruthyunjaya P, Schefler AC et al. Practice patterns for the treatment of uveal melanoma with iodine-125 plaque brachytherapy: Ocular Oncology Study Consortium Report 5. Ocul Oncol Pathol 2020; 6: 210-218.